ABBV — AbbVie Inc. stock price and chart

ABBV

$286.39-0.12%

as of close, Oct 27, 2026

☾ AH $286.39 -0.12%

AbbVie Inc.Stock · HealthcareS&P 500 · 0.7% of SPYRussell 1000 · 0.6% of IWBUS Stock Market · 0.6% of VTIRussell 3000 · 0.6% of IWVMSCI World · 0.5% of URTHMSCI ACWI · 0.4% of ACWIS&P 500 Equal Weight · 0.2% of RSP

PeersJNJMRKLLYBMYNVSAMGN

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDED

20162019202120242026

60.080.0100.0120.0140.0160.0180.0200.0220.0240.0260.0280.00100.0M200.0M$286.39

2026-10-27

Price$286.39

MA20$251.85

MA50$233.19

Vol18.6M

What would $1,000 invested in ABBV be worth today? →

ABBV returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $286.39
YTD price return: +25.34%
YTD total return: +29.09%
Next earnings: Oct 30, 2026 · Before open
Market cap: 506.1B2016-12 101.8B2026-10 506.1B+397.3% over the window
Enterprise value: 562.9B
Shares outstanding: 1.8B2016-06 1.6B2026-06 1.8B+8.5% over the window
52W low: $190.75
52W high: $291.40
From 52W high: -1.72%
From 52W low: +50.14%
52W range: 95%
Beta: 0.29

Volume

Rel volume: 0.68×
30D volume: 4.8M
30D $ vol: 1.3B

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1MNo open-market insider purchase or sale with a transaction date in the last 30 days, as filed on Form 4.: none
Insider net 3M0 insider-days of buying (no priced lot) and 1 of selling ($8.2M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$8.2M
Insider net 1Y0 insider-days of buying (no priced lot) and 4 of selling ($18.9M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$18.9M

Form 4 transactions by trade date, as filed; latest on file 2026-08-14.

Fundamentals

Sales (ttm): 64.4B2016-06 24.8B2026-06 64.4B+160.1% over the window
Sales/share: $36.442016-06 $15.202026-06 $36.44+139.7% over the window
EPS (ttm): $3.542016-06 $3.472026-06 $3.54+2.0% over the window
FCF (ttm): 18.2B2016-06 7.6B2026-06 18.2B+138.4% over the window
FCF/share: $10.302016-06 $4.692026-06 $10.30+119.7% over the window
Book value/share: -$3.362016-06 $3.462026-06 -$3.36-197.0% over the window
Net margin: 9.80%2016-06 23.1%2026-06 9.8%-57.6% over the window
ROA: 4.67%2016-06 8.5%2026-06 4.7%-45.1% over the window
Current ratio: 0.812016-06 1.812026-06 0.81-55.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: +10.39%2025-06-30 → 2026-06-3058.3B → 64.4B (+10.4% total)+4.75%2023-06-30 → 2026-06-3056B → 64.4B (+14.9% total)+3.69%2021-06-30 → 2026-06-3053.7B → 64.4B (+19.8% total)+10.03%2016-06-30 → 2026-06-3024.8B → 64.4B (+160.1% total)
Net income: +67.74%2025-06-30 → 2026-06-303.8B → 6.3B (+67.7% total)-10.10%2023-06-30 → 2026-06-308.7B → 6.3B (-27.3% total)-1.08%2021-06-30 → 2026-06-306.7B → 6.3B (-5.3% total)+0.99%2016-06-30 → 2026-06-305.7B → 6.3B (+10.3% total)
FCF: -0.16%2025-06-30 → 2026-06-3018.2B → 18.2B (-0.2% total)-9.78%2023-06-30 → 2026-06-3024.8B → 18.2B (-26.6% total)-1.43%2021-06-30 → 2026-06-3019.6B → 18.2B (-7.0% total)+9.08%2016-06-30 → 2026-06-307.6B → 18.2B (+138.4% total)
Shares: +0.03%2025-06-30 → 2026-06-301.8B → 1.8B (+0.0% total)+0.04%2023-06-30 → 2026-06-301.8B → 1.8B (+0.1% total)-0.00%2021-06-30 → 2026-06-301.8B → 1.8B (-0.0% total)+0.82%2016-06-30 → 2026-06-301.6B → 1.8B (+8.5% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +68.63%2025-06-30 → 2026-06-30$2.10 → $3.54 (+68.6% total)-10.02%2023-06-30 → 2026-06-30$4.86 → $3.54 (-27.2% total)-0.93%2021-06-30 → 2026-06-30$3.71 → $3.54 (-4.6% total)+0.20%2016-06-30 → 2026-06-30$3.47 → $3.54 (+2.0% total)
Sales/share: +10.36%2025-06-30 → 2026-06-30$33.02 → $36.44 (+10.4% total)+4.70%2023-06-30 → 2026-06-30$31.74 → $36.44 (+14.8% total)+3.69%2021-06-30 → 2026-06-30$30.40 → $36.44 (+19.8% total)+9.14%2016-06-30 → 2026-06-30$15.20 → $36.44 (+139.7% total)
FCF/share: -0.19%2025-06-30 → 2026-06-30$10.32 → $10.30 (-0.2% total)-9.82%2023-06-30 → 2026-06-30$14.05 → $10.30 (-26.7% total)-1.43%2021-06-30 → 2026-06-30$11.08 → $10.30 (-7.0% total)+8.19%2016-06-30 → 2026-06-30$4.69 → $10.30 (+119.7% total)
Dividend/share: +5.57%2025-06-30 → 2026-06-30$6.47 → $6.83 (+5.6% total)+5.30%2023-06-30 → 2026-06-30$5.85 → $6.83 (+16.8% total)+6.44%2021-06-30 → 2026-06-30$5.00 → $6.83 (+36.6% total)+11.90%2016-06-30 → 2026-06-30$2.22 → $6.83 (+207.7% total)
Price: +25.61%2025-10-27 → 2026-10-27$228.03 → $286.39 (+25.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+27.26%2023-10-27 → 2026-10-27$138.93 → $286.39 (+106.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+21.45%2021-10-27 → 2026-10-27$108.40 → $286.39 (+164.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+16.72%2016-10-26 → 2026-10-27$61.02 → $286.39 (+369.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +29.37%2025-10-27 → 2026-10-27$221.40 → $286.39 (+29.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+31.56%2023-10-27 → 2026-10-27$125.74 → $286.39 (+127.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+25.84%2021-10-27 → 2026-10-27$90.76 → $286.39 (+215.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+21.57%2016-10-26 → 2026-10-27$40.60 → $286.39 (+605.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 80.9×2016-12 16.742026-10 80.21+379.1% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 30.0×2016-12 11.142026-10 30.00+169.4% over the window
Fwd P/E: 17.6×
P/S (ttm)Market cap ÷ TTM revenue.: 7.9×2016-12 4.032026-10 7.86+95.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: -85.3×2016-12 15.732026-10 -85.28-642.1% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 27.8×2016-12 14.642026-10 27.79+89.9% over the window
EV/EBITDA (fy): 22.7×
EV/Sales (ttm): 8.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 3.60%2016-09 6.8%2026-06 4.1%-40.3% over the window
Dividend yield (fwd)Indicated annual dividend ÷ last close: the last regular payment × payments a year, from our own dividend record. Shown only for a company that pays the same amount each time (raises and cuts allowed), whose payments are on schedule and agree with the dividends it reports paying; a company whose payments vary in size, such as an unequal interim and final, has no forward figure — see the ttm yield.: 2.42%
Dividend yield (ttm)Dividends paid over the last year ÷ last close: the last full cycle of regular payments in our own dividend record. Below the forward yield after a raise, above it after a cut. Shown only when the record holds that full cycle and it agrees with the dividends the company reports paying; otherwise —.: 2.42%
Dividend/share (fwd)The indicated annual dividend: the last regular payment × payments a year, for a company that pays the same amount each time.: $6.92
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 1.77B ÷ 1.77B. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -0.03%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-0.03%) + dividends paid over that year ($12B) ÷ market_cap_at(2025-06-30) ($327.9B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.62%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($1.5B) ÷ today's market cap ($506.1B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.30%2016-09 5.4%2026-06 0.3%-93.7% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $1.5B + TTM dividends $12B) ÷ today's market cap ($506.1B). Same caveat as the cash buyback yield.: 2.66%2016-09 8.9%2026-06 3.0%-66.2% over the window

Vs own 10Y history

P/E: 88th
P/OI: 90th
P/S: 100th
P/B: 97th
P/FCF: 100th

Bar = where today’s multiple sits in ABBV’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-27#

-0.12%

-0.93%

+8.34%

+11.47%

YTD

+25.34%

+25.59%

+164.20%

Recent filings#

Oct 58-K · Results of operations
Sep 38-K · AbbVie Completes Acquisition of Apogee Therapeutics
Aug 14Insider sale · Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) sold 32,710 shares for $8.2M at $250.00
Jul 31Earnings · Earnings release — EPS $3.65 vs $3.64 est. (+0.3%); revenue $16.99B (+10% y/y) 2.5%
Jul 68-K · Results of operations

All filings and insider trades →

Financial statements

Open full ABBV financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+8.32%	+0.22%
JNJ	Johnson & Johnson	-0.92%	+0.91%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+8.98%	-0.08%
MRK	Merck & Co. Inc.	-4.68%	+0.86%
NVS	Novartis AG	+7.84%	+1.98%
TMO	Thermo Fisher Scientific Inc.	+2.67%	+1.19%
AMGN	Amgen Inc.	+8.04%	+0.75%
GILD	Gilead Sciences Inc.	+5.40%	+0.25%

ABBV — AbbVie Inc. price, chart and key statistics